Theres a ustekinumab biosimilar, CT-P43 - In a multinational, phase III study in 509 plaque psoriasis pts, CT-P43 was equivalent to the originator, Stelara, with week 16 PASI75 scores of 78% vs 76%, and continued efficacy out to week 40 https://t.co/dEImEp8l90 https://t.co/UoqGgaad8H
Links:
CT-P43 Shows Equivalent Efficacy, Safety for Plaque Psoriasis vs Ustekinumab
https://bit.ly/3N56MTs
29-11-2023